首页> 外文OA文献 >Using Convergent Mixed Methods To Evaluate Treatment Risks and Benefits In Rare Disease: An Example From A Phase Ii Registration Trial In Metastatic Merkel Cell Carcinoma

【2h】

Using Convergent Mixed Methods To Evaluate Treatment Risks and Benefits In Rare Disease: An Example From A Phase Ii Registration Trial In Metastatic Merkel Cell Carcinoma

机译：使用收敛混合方法评估稀有疾病中的治疗风险和益处：来自转移梅尔克尔细胞癌中的II期登记试验的一个例子

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
M Bharmal; I Guillemin; A Marrel; J Lambert; B Arnould; F Fatoumata; M Hennessy; C Dias-Barbosa;
展开▼
作者单位

展开▼
年度 2017
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial [J] . Murtuza Bharmal, Isabelle Guillemin, Alexia Marrel, Orphanet journal of rare diseases . 2018,第1期

机译：如何应对评估罕见病中治疗获益风险的挑战？一种融合混合方法在默克尔细胞癌2期临床试验中的应用
2. Patient Experiences with Avelumab in Treatment-Naive Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial [J] . Lambert Jeremy, Marrel Alexia, DAngelo Sandra P., The patient . 2020,第4期

机译：患者与Avelumab治疗 - 天真转移性Merkel细胞癌的经验：来自Javelin Merkel 200的纵向定性访谈结果，注册临床试验
3. Avelumab in patients with previously treated metastatic Merkel cell carcinoma: long-term data and biomarker analyses from the single-arm phase 2 JAVELIN Merkel 200 trial [J] . Sandra P DAngelo, Shailender Bhatia, Andrew S Brohl, Journal for ImmunoTherapy of Cancer . 2020,第1期

机译：患有先前治疗的转移梅尔克尔细胞癌的患者的Avelumab：从单臂阶段2标枪Merkel 200试验中分析了长期数据和生物标志物
4. Designing Phase III Trials in Metastatic Renal Cell Carcinoma: What Are the New Standards? [C] . Ana M. Molina Genitourinary Cancers Symposium . 2012

机译：在转移性肾细胞癌中设计III期试验：新标准是什么？
5. Development and evaluation of the assessment of opioid taking behaviors and adherence (AOTBA) scale in patients with sickle cell disease: A multi-phase, mixed methods study [D] . Alsalman, Abdulkhaliq Jassem 2013

机译：镰状细胞病患者阿片类药物服用行为和依从性（AOTBA）量表的评估与开发：多阶段，混合方法研究
6. How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial [O] . Murtuza Bharmal, Isabelle Guillemin, Alexia Marrel, 2018

机译：如何应对评估罕见病中治疗获益风险的挑战？融合混合方法在默克尔细胞癌2期临床试验中的应用
7. How to address the challenges of evaluating treatment benefits-risks in rare diseases? A convergent mixed methods approach applied within a Merkel cell carcinoma phase 2 clinical trial [O] . Murtuza Bharmal, Isabelle Guillemin, Alexia Marrel, 2018

机译：如何应对稀有疾病评估治疗效益的挑战？在Merkel细胞癌期临床试验中应用的收敛混合方法方法

Using Convergent Mixed Methods To Evaluate Treatment Risks and Benefits In Rare Disease: An Example From A Phase Ii Registration Trial In Metastatic Merkel Cell Carcinoma

著录项

引文网络

相似文献

相关主题

期刊订阅